Journal Title
MOLECULAR CANCER RESEARCH

MOL CANCER RES

ISSN / eISSN
1541-7786 / 1557-3125
Aims and Scope
Molecular Cancer Research publishes articles describing novel basic cancer research discoveries of broad interest to the field. Studies must be of demonstrated significance, and the journal prioritizes analyses performed at the molecular and cellular level that reveal novel mechanistic insight into pathways and processes linked to cancer risk, development, and/or progression. Areas of emphasis include all cancer-associated pathways (including cell-cycle regulation; cell death; chromatin regulation; DNA damage and repair; gene and RNA regulation; genomics; oncogenes and tumor suppressors; signal transduction; and tumor microenvironment), in addition to studies describing new molecular mechanisms and interactions that support cancer phenotypes. For full consideration, primary research submissions must provide significant novel insight into existing pathway functions or address new hypotheses associated with cancer-relevant biologic questions.
Subject Area

CELL BIOLOGY

ONCOLOGY

CiteScore
9.90 View Trend
CiteScore Ranking
Category Quartile Rank
Medicine - Oncology Q1 #63/404
Medicine - Molecular Biology Q1 #77/410
Medicine - Cancer Research Q1 #54/230
Web of Science Core Collection
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
Category (Journal Citation Reports 2024) Quartile
CELL BIOLOGY Q2
ONCOLOGY Q2
H-index
124
Country/Area of Publication
UNITED STATES
Publisher
American Association for Cancer Research Inc.
Publication Frequency
Monthly
Year Publication Started
2002
Annual Article Volume
102
Open Access
NO
Contact
AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now